Paper41209019
Osteosarcoma immunometabolism: emerging mechanisms and clinical implications.
Tan B and 1 other. Front Immunol, 2025. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Osteosarcoma immunometabolism: emerging mechanisms and clinical implications. Papers, record 41209019. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41209019
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Osteosarcoma | Major topic |
| Tumor Microenvironment | Major topic |
| Bone Neoplasms | Major topic |
| Energy Metabolism | Major topic |
| Humans | |
| Immunotherapy | |
| Animals |
Source PubMed
References157
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35461343 | ANGPTL4 negatively regulates the progression of osteosarcoma by remodeling branched-chain amino acid metabolism. | Cell Death Discov | 2022 | https://conductscience.org/library/papers/35461343 | PubMed |
| 2 | 38486485 | FASN Inhibition Decreases MHC-I Degradation and Synergizes with PD-L1 Checkpoint Blockade in Hepatocellular Carcinoma. | Cancer Res | 2024 | https://conductscience.org/library/papers/38486485 | PubMed |
| 3 | 37528150 | NUCKS1, a LINC00629-upregulated gene, facilitated osteosarcoma progression and metastasis by elevating asparagine synthesis. | Cell Death Dis | 2023 | https://conductscience.org/library/papers/37528150 | PubMed |
| 4 | 30914826 | Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. | Nat Rev Clin Oncol | 2019 | https://conductscience.org/library/papers/30914826 | PubMed |
| 5 | 37605057 | Glutarate regulates T cell metabolism and anti-tumour immunity. | Nat Metab | 2023 | https://conductscience.org/library/papers/37605057 | PubMed |
| 6 | 39154340 | Inherent preference for polyunsaturated fatty acids instigates ferroptosis of Treg cells that aggravates high-fat-diet-related colitis. | Cell Rep | 2024 | https://conductscience.org/library/papers/39154340 | PubMed |
| 7 | 30151352 | Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy. | Front Oncol | 2018 | https://conductscience.org/library/papers/30151352 | PubMed |
| 8 | 37209607 | Baicalin induces ferroptosis in osteosarcomas through a novel Nrf2/xCT/GPX4 regulatory axis. | Phytomedicine | 2023 | https://conductscience.org/library/papers/37209607 | PubMed |
| 9 | 40154215 | Ultra-sensitive detection of melanoma NRAS mutant ctDNA based on programmable endonucleases. | Cancer Genet | 2025 | https://conductscience.org/library/papers/40154215 | PubMed |
| 10 | 30338824 | Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression. | Eur Rev Med Pharmacol Sci | 2018 | https://conductscience.org/library/papers/30338824 | PubMed |
| 11 | 36462545 | Fatty acid transport proteins (FATPs) in cancer. | Chem Phys Lipids | 2023 | https://conductscience.org/library/papers/36462545 | PubMed |
| 12 | 33580363 | Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. | Cancer Immunol Immunother | 2021 | https://conductscience.org/library/papers/33580363 | PubMed |
| 13 | 33503424 | Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. | Cell Rep | 2021 | https://conductscience.org/library/papers/33503424 | PubMed |
| 14 | 28604752 | Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. | Oncogene | 2017 | https://conductscience.org/library/papers/28604752 | PubMed |
| 15 | 29176561 | HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. | Nat Commun | 2017 | https://conductscience.org/library/papers/29176561 | PubMed |
| 16 | 36814318 | Functional heterogeneity of MCT1 and MCT4 in metabolic reprogramming affects osteosarcoma growth and metastasis. | J Orthop Surg Res | 2023 | https://conductscience.org/library/papers/36814318 | PubMed |
| 17 | 33589820 | Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. | Nature | 2021 | https://conductscience.org/library/papers/33589820 | PubMed |
| 18 | 18775299 | Cancer cell metabolism: Warburg and beyond. | Cell | 2008 | https://conductscience.org/library/papers/18775299 | PubMed |
| 19 | 38025952 | A new ferroptosis-related signature model including messenger RNAs and long non-coding RNAs predicts the prognosis of gastric cancer patients. | J Transl Int Med | 2023 | https://conductscience.org/library/papers/38025952 | PubMed |
| 20 | 37304579 | Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma. | Mater Today Bio | 2023 | https://conductscience.org/library/papers/37304579 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42953799 | Metabolic State Machines and Nutritional Ecology: A New Framework for Osteosarcoma Therapy. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42953799 | PubMed |
| 42745749 | Metabolic reprogramming-related drug resistance in osteosarcoma: from molecular mechanisms to therapeutic translation. | Front Mol Biosci | 2026 | https://conductscience.org/library/papers/42745749 | PubMed |
| 42681084 | Identification of a metastasis-associated prognostic gene signature in osteosarcoma through integrated bioinformatics and functional analysis. | Mamm Genome | 2026 | https://conductscience.org/library/papers/42681084 | PubMed |
| 42454278 | Re-Arming the Immunological Radar: The Translational Landscape of Dendritic Cell-Centric Nanotherapeutics and Microenvironment Remodeling for Osteosarcoma. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42454278 | PubMed |
| 42143177 | Machine learning-based integrative analysis identifies CXCL13-driven tertiary lymphoid structures as favorable immune and prognostic features in osteosarcoma. | Cell Oncol (Dordr) | 2026 | https://conductscience.org/library/papers/42143177 | PubMed |
| 41953014 | Immune exclusion as a recurrent immune-escape state driving treatment resistance in osteosarcoma: insights from single-cell, spatial, and multi-omics studies. | Front Immunol | 2026 | https://conductscience.org/library/papers/41953014 | PubMed |
| 41892359 | Cell-Cell Interactome-Based Pathogenesis and Therapies for Osteosarcoma. | Cells | 2026 | https://conductscience.org/library/papers/41892359 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41209019
GET https://conductscience.org/api/papers/v1/41209019/references?page=2